Targets › 3C
1 program from 1 company in 9 trials: 7 Phase 2, 1 Phase 3, 1 Phase 4; Infectious disease; next expected readout Sep 2027.
Open in Phaseline: the race on 3C, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Remdesivir RNA-directed RNA polymerase L inhibitor; Replicase polyprotein 1ab inhibitor | 3C, RDRP | Phase 3 | COVID-19 Infection; SARS CoV-2 Post-Acute Sequelae; COVID-19; COVID - 19 … | Sep 2027 |
COVID-19 (3) COVID-19 Infection (1) SARS CoV-2 Post-Acute Sequelae (1) COVID - 19 (1) Respiratory Syncytial Virus (RSV) (1) Hematopoietic and Lymphatic System Neoplasm (1) Dengue (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.